Tumor cell survival and resistance to therapy

Current Opinion in Hematology

Volumn 3, Issue 4, 1996, Pages 279-287

  Arceci, Robert J ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; APOPTOSIS; CELL DEATH; CELL KILLING; CELL SURVIVAL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 0030038611     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603040-00006     Document Type: Review

References (89)

1. Goldstein LJ: Clinical reversal of drug resistance. Curr Probl Cancer 1995, 19:65-124.
2. Chan HS, DeBoer G, Haddad G, Gallie BL, Ling V: Multidrug resistance In pedlatric malignancies. Hematol Oncol Clin North Am 1995, 9:275-318.
3. de Wind N, Dekker M, Berns A, Radman M, te Riele H: Inactivation of the •• mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995, 82:321-330. Using homologous recombination, these authors generated mice that completely lack the gene encoding the Msh2 protein. The manuscript definitively proves the importance of the Msh2 gene in DNA mismatch repair and hyperrecombination and furthermore shows that such defects in DNA repair predispose the animals to developing malignancies. Importantly, this paper also demonstrates that lack of Msh2 activity also leads to increased resistance to methylating drugs, thus linking cellular systems of DNA repair with cancer predisposition and drug resistance.
4. Delville JP, Pradier O, Pauwels O, Van Onderbergen A, Kiss R, Feremans W, Capel P: Comparative study of multidrug resistance evaluated by means of the quantitative immunohlstochemical detection of P-glycoprotein and the functional release of rhodamine 123. Am J Hematol 1995, 49:183-193.
5. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL: Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and HDR1+/efflux- cases. Blood 1995, 86:2329-2342. A clearly written report on flow cytometric approaches to measuring both MDR1 P-glycoprotein expression and function. This paper also definitively shows that the expression of MDR1 P-glycoprotein does not necessarily result in functional drug efflux.
6. Sievers E, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL, • Bernstein ID: Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pedlatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Leukemia 1995, 9:2042-2048. This is a flow cytometric analysis of MDR P-glycoprotein in childhood AML specimens demonstrating some of the limits and problems of P-glycoprotein analysis.
7. Kang YK, Zhan Z, Regis J, Robey R, Meadows B, Dickstein B, Lee JS, Otsuki T, Stetler-Stevenson M, Jaffe ES, Solomon D, Wilson WH, Fojo A, Bates SE: Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995, 86:1515-1524. A clearly written description of the methodology of using reverse transcriptase polymerase chain reaction in the determination of MDR1 mRNA.
8. Funato T: Rapid diagnosis of drug-resistant genes by PCR assay. Rinsho Byori 1995, 43:535-539.
9. Moretti JL, Caglar M, Boaziz C, Caillat-Vigneron N, Morere JF: Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrils and indlum-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer? Eur J Nucl Med 1995, 22:177-180.
10. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI: • Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833 [ses comments]. J Natl Cancer Inst 1995, 87:1593-1802. This paper shows that selection of multidrug resistance in the presence of the MOR1 P-glycoprotein inhibitor, PSC 833, results in the suppression of mdr1 gene expression. Such results suggest that the use of MDR1 inhibitors may be useful during initial treatments, thereby reducing the chance of selecting for cells with increased MDR1 P-glycoprotein expression.
11. Eliason JF, Ramuz H, Yoshikubo T, Ishikawa T, Yamamoto T, Tsuruo T: Novel dithiane analogues of tiapamll with high activity to overcome multidrug resistance in vitro. Biochem Pharmacol 1995, 50:187-196.
12. Zibera C, Gibelli N, Maestri L, Della Cuna GR: Medroxyprogesteroneacetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line. Anticancer Res 1995, 15:745-749.
13. Sela S, Husain SR, Pearson JW, Longo DL, Rahman A: Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamll. J Natl Cancer Inst 1995, 87:123-128.
14. Walther W, Stein U, Pfeil D: Gene transfer of human TNF alpha into • glloblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity. Int J Cancer 1995, 61:832-839. This study shows that MDR1 P-glycoprotein expression and function can be suppressed in highly treatment-resistant glioblastoma cells following the transduction and expression of the cDNA encoding tumor necrosis factor a. Concomitantly, the glioblastoma cells are shown to become drug sensitive again, demonstrating that gene therapy with specific cytokines may also be useful for sensitizing drug-resistant tumors to chemotherapy.
15. O'Connor R, Liu C, Ferris CA, Guild BC, Teicher BA, Corvi C, Liu Y, Arceci RJ, Goldmacher VS, Lambert JM, Blattler WA: Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 1995, 86:4286-4294. This paper demonstrates the possibilities of using monoclonal antibodies as targeting agents for the tumor-specific delivery of agents that can alter chemotherapy resistance mechanisms, thus providing methods by which to increase the effectiveness of treatment regimens.
16. Goldsmith ME, Gudas JM, Schneider E, Cowan KH: Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995, 270:1984-1898.
17. Doyle LA, Ross DD, Ordonez JV, Yang W, Gao Y, Tong Y, Belani CP, Gutheil JC: An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br J Cancer 1995, 72:535-542.
18. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N, Nakamura M: Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 1995, 72:550-554.
19. Eijdems EW, Zaman GJ, de Haas M, Versantvoort CH, Flens MJ, Scheper RJ, Kamst E, Borst P, Baas F: Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells. Br J Cancer 1995, 72:298-306.
20. Eijdems EW, De Haas M, Coco-Martin JM, Ottenheim CP, Zaman GJ, Dauwerse HG, Breuning MH, Twentyman PR, Borst P, Baas F: Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 1995, 60:676-684.
21. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP, Sehested M: Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 1995, 55:459-462.
22. Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandas DJ, Germino JF, and Sartorelli AC: Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Res 1995, 55:4352-4360.
23. Zhou DC, Zittoun R, Marie JP: Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995, 9:1661-1666.
24. Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Schefffer GL, Scheper RJ: The LRP gene encoding a major value protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 1995, 55:4214-4219.
25. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, De Vries EGE, Scheper RJ: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995, 87:1230-1237.
26. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J: MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 1995, 10:2001-2006.
27. Lanza F, Bi S, Moretti S, Castoldi G, Goldman JM: Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides. Br J Haematol 1995, 90:8-14.
28. Nooter K, Boersma AW, Oostrum RG, Burger H, Jochemsen AG, Stoter • G: Constitutive expression of the c-H-ras oncogene Inhibits doxorubicin-Induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 1995, 71:558-561. An interesting paper linking the proliferative function of the mutated ras oncogene to the inhibition of drug-induced programmed cell death.
29. Bomer MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E: • Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995, 55:2122-2128. An interesting paper showing that p53-independent mechanisms of apoptosis must exist and contribute to chemotherapeutic drug resistance.
30. Hsu H, Xiong J, Goeddel DV: The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 1995, 81:495-504. The newly described TRADD protein is shown to associate with the tumor necrosis factor receptor and play a critical role in apoptosis. This paper also links this programmed cell death program to the activation of the transcription factor, NF-κB.
31. Stanger BZ, Leder P, Lee T-H, Kim E, Seed B: RIP: a novel protein containing a death domain that interacts with Fas/APO-1(CD95) in yeast and causes cell death. Cell 1995, 81:513-523. This paper, along with the papers by Chinnaiyan et al. (Cell 1995, 81:505-512), Boldin et al. (J Biol Chem 1995, 270:7795-7798), and Sato (Science 1995, 268:411-415), represents the beginning of the identification of the multiple downstream molecular signals following stimulation of the death-inducing Fas receptor.
32. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death • domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512. This paper, along with the papers by Stanger et al. (Cell 1995, 81:513-523), Boldin et al. (J Biol Chem 1995, 270:7795-7798), and Sato et al. (Science 1995, 268:411-415), represents the beginning of the identification of the multiple downstream molecular signals following stimulation of the death-inducing Fas receptor.
33. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D: A novel protein that interacts with the death domain of Fas/AP01 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798. This paper, along with the papers by Stanger et al. (Cell 1995, 81:513-523), Chinnaiyan et al. (Cell 1995, 81:505-512), and Sato (Science 1995, 268:411-415), represents the beginning of the identification of the multiple downstream molecular signals following stimulation of the death-inducing Fas receptor.
34. Sato T, Irie S, Kitada S, and Reed JC: FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995, 268:411-415. This paper, along with the papers by Stanger et al. (Cell 1995, 81:513-523), Chinnaiyan et al. (Cell 1995, 81:505-512), and Boldin et al. (J Biol Chem 1995, 270:7795-7798) represents the beginning of the identification of the multiple downstream molecular signals following stimulation of the death-inducing Fas receptor.
35. Cory S: Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 1995, 13:513-543.
36. Minn AJ, Rudin CM, Boise LH, Thompson CB: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 1995, 86:1903-1910.
37. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995, 55:4471-4478.
38. Sumantran VN, Ealovega MW, Nunez G, Clarke MF, Wicha MS: Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 1995, 55:2507-2510.
39. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: •• Cloning and functional analysis of BAG-1: a novel bcl-2-binding protein with anti-cell death activity. Cell 1995, 80:279-284. This paper describes the cloning by protein interacting methods, of a novel protein structurally unrelated to bcl-2, but nevertheless able to interact with the bcl-2 system of proteins. BAG-1 is shown to contribute to inhibition of programmed cell death secondary to a variety of stimuli, including cytolytic lymphocyte activity. Thus BAG-1 may represent a novel pathway controlling programmed cell death but also showing the complex array of molecular interactions that occur with the bcl-2 family of proteins.
40. L-interacting protein, termed Bad, which is able to promote programmed cell death through its ability to displace the Bax protein from these two life-promoting molecules. The importance of the quantitative balance of levels of these proteins is convincingly demonstrated by correlating resistance to programmed cell death in cell lines expressing different amounts of these regulatory molecules.
41. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299. This study demonstrates a possible link between the tumor suppressor protein, p53, known to play an important role in many forms of genotoxic agent-induced apoptosis, with the transcriptional activation of the bax gene, another critical regulator of programmed cell death.
42. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic • drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995, 55:3902-3907. This study shows an important association of estrogen exposure and the induction of bcl-2 expression in breast cancer cells resulting in increased chemotherapeutic drug resistance. Such a link may in part offer a rationale for using combination chemotherapy with antiestrogens in the treatment of breast cancer.
43. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP: • Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995, 55:735-738. This paper shows that androgen is able to induce bcl-2 and thus resistance to etoposide in prostate cancer cells. Antisense ogligonucleotides inhibiting bcl-2 expression and function are able to block the protective effect of androgens on etoposide cytotoxicity. Thus this study suggests that androgen depletion plus combination chemotherapy may be a reasonable approach in drug-resistant prostate cancer.
44. Xue D, Horvitz HR: Inhibition of the Caenorhabditls elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein. Nature 1995, 377:248-251.
45. Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Droge W, Krammer PH, Fiers W, Schuize-Osthoff K: Requirement of an ICE/CED-3 protease for Fas-APO-1-mediated apoptosis. Nature 1995, 375:81-83.
46. Munday NA, Vaillancourt JP, Ali A, Casano FJ, Miller DK, Molineaux SM, Yamin TT, Yu VL, Nicholson DW: Molecular cloning and pro-apoptotic activity of ICEreIII and ICEreIIII, members of the ICE/CED-3 family of cysteine proteases. J Biol Chem 1995, 270:15870-15876.
47. Kamens J, Paskind M, Hugunin M, Talanian RV, Allen H, Banach D, Bump N, Hackett M, Johnston CG, Li P, Mankovich JA, Terranova M, Ghayur T: Identification and characterization of ICH-2, a novel member of the interleukin-1 beta-converting enzyme family of cysteine proteases. J Biol Chem 1995, 270:15250-15256.
48. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier •• GG, Salvesen GS, Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995, 81:801-809. Describes a new protease, termed YAMA (for the Hindu God of death) that may be a critical activator of the PARP system of recognizing DNA strand breaks and repair. Importantly, YAMA is also shown to be uniquely inhibitable with CrmA, thus providing a molecular explanation of CrmA inhibition of apoptosis.
49. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithellal cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493-501.
50. Lazebnik YA, Takahashi A, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Eamshaw WC: Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 1995, 92:9042-9046.
51. Schreiber V, Hunting D, Trucco C, Gowans B, Grunwald D, De Murcia G, De Murcia JM: A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. Proc Natl Acad Sci USA 1995, 92:4753-4757.
52. Heller B, Wang ZQ, Wagner EF, Radons J, Burkle A, Fehsel K, Burkart V, Kolb H: Inactivation of the poly(ADP-ribose) polymerase gene affects oxygen radical and nitric oxide toxicity in islet cells. J Biol Chem 1995, 270:11176-11180.
53. Mizumoto K, Farber JL: Growth inhibition and cell killing by N-methyl-N-nitrosourea: metabolic alterations that accompany poly(ADP-ribosyl)ation. Arch Biochem Biophys 1995, 319:512-518.
54. Kupper JH, Muller M, Jacobson MK, Tatsumi-Miyajima J, Coyle DL, Jacobson EL, Burkle A: Trans-dominant inhibition of poly(ADP-ribosyl)ation sensitizes cells against gamma-irradiation and N-methyl-N'-nitro-N-nitrosoguanldine but does not limit DNA replication of a polyomavirus replicon. Mol Cell Biol 1995, 15:3154-3163.
55. Kumar S: Inhibition of apoptosis by the expression of antisense Nedd2. FEBS Lett 1995, 368:69-72.
56. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hitton J, Jones RJ: BCR-ABL-mediated Inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticencer agents. Blood 1995, 86:1148-1158. This paper nicely shows how the fusion product bcr-abl is fundamental to the underlying resistance through programmed cell death inhibition of certain types of cancer to multiple anticancer drugs. Emphasis is made on the association of translocation events and their products on both cell growth and resistance mechanisms of malignant cells.
57. Muthukkumar S, Nair P, Sells SF, Maddiwar NG, Jacob RJ, Rangnekar VM: Role of EQR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. Mol Cell Biol 1995, 15:6262-6272.
58. Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ: Phosphorothloate BCR-ABL antisensa ollgonucleotides induce cell death, but fall to reduce cellular bcr-abl protein levels. Leukemia 1995, 9:118-130.
59. Keith FJ, Bradbury DA, Zhu YM, Russell NH: Inhibition of bcl-2 with antisense ollgonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995, 9:131-138.
60. Kimura SS, Maekawa T, Hirakawa K, Murakami A, Abe T: Alterations of c-myc expression by antisense ollgodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995, 55:1379-1384.
61. Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, McDonnell TJ: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 1995, 93:147-155.
62. Azuma M, Lanier LL: The role of CD28 costimulation in the generation of cytotoxic T lymphocytes. Curr Top Microbiol Immunol 1995, 198:59-74.
63. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Gribben JG, Nadler LM: B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-1. Immunity 1995, 2:523-532. This paper demonstrates the complexity of the B7 family of costimulatory molecules by showing that signaling induced by B7-2 and B7-1 results in distinct T-lymphocyte responses.
64. DeBenedette MA, Chu NR, Pollok KE, Hurtado J, Wade WF, Kwon BS, Watts THE: Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 1995, 181:985-992.
65. Gajewski TF, Renauld JC, Van Pel A, Boon T: Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol 1995, 154:5637-5648.
66. Sharpe AH: Analaysis of lymphocyte Costimulation in vivo using transgenic and "knockout" mice. Curr Opin Immunol 1995, 7:389-395.
67. Bluestone JA: New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995, 2:555-559.
68. Mukherji B, Chakraborty NG: Immunobiology and Immunotherapy of melanoma. Curr Opin Oncol 1995, 7:175-184.
69. Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an • Immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995, 181:2109-2117. An important paper documenting the identification of the HER-2/new protooncogene as an ovarian carcinoma-specific antigen recognized by CD8+ cytotoxic T lymphocytes. The generation of specific cytotoxic T-lymphocyte responses to this self-antigen should serve as an interesting model for immunologic tolerance to tumors.
70. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon • T, van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995, 2:167-175. This paper describes the identification of a new immunogenic melanoma antigen called BAGE. This 43-amino-acid protein is not expressed in normal tissue with the exception of the testis, similar to the expression pattern observed with the MAGE melanoma tumor antigens.
71. Woods AS, Huang AY, Cotter RJ, Pastemack GR, Pardoll DM, Jaffee EM: •• Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 1995, 226:15-25. This paper describes the use of important new methods for the sequence analysis of femtomolar amounts of protein or peptides. The enhanced sensitivity of this method provides the means by which to isolate and sequence tumor-specific antigens, many of which may be in relatively low abundance on the surface of tumor cells.
72. Bernard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA: Generation of immunostimulatory dendritic cells from human CD34+ hematopoletic progenitor cells of the bone marrow and peripheral blood. Cancer Res 1995, 55:1099-1104.
73. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995, 55:3369-3373.
74. Kroesen BJ, Bakker A, van Lier RA, The HT, De Leij L: Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CDS and CD28. Cancer Res 1995, 55:4409-4415.
75. Matulonis UA, Dosious C, Lamont C, Freeman GJ, Mauch P, Nadler LM, • Griffin JO: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995, 85:2507-2515. Using a myeloid cell line made leukemogenic by the expression of bcr-abl, this manuscript shows how the transduction of the cDNA encoding the B7-1 costimulatory molecule can elicit an antileukemic immune response, thus proving to be a potentially interesting model for the treatment of human cancers.
76. Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray • GS, Orchard PJ, Blazar BR: B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Ther 1995, 2:39-46. This work utilizes a murine neuroblastoma model to show that even with the expression of the B7-1 costimulatory receptors, the relative deficiency of major histocompatibility complex expression limits the role of costimulation in immune-mediated antitumor activity.
77. Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, • Eisenbach L: Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995, 1:1179-1183. This manuscript shows the potential utility of using tumor-specific peptide antigens in treating neoplastic disease by demonstrating the prevention of metastases in a murine lung carcinoma model.
78. Monach P, Meredith S, Siegel C, Schreiber H: A unique tumor antigen produced by a single amino acid substitution. Immunity 1995, 2:45-49.
79. Melief C, Kast M: T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol Rev 1995, 146:167-177.
80. Antonia SJ, Munoz-Antonia T, Soidevila G, Miller J, Flavell RA: B7-1 expression by a non-antigen presenting cell-derived tumor. Cancer Ras 1995, 55:2253-2256.
81. Pardoll DM: Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995, 13:399-415.
82. Vieweg J, Gilboa E: Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Invest 1995, 13:193-201.
83. Sun WH, Burkholder JK, Sun J, Culp J, Turner J, Lu XG, Pugh TD, Ershler WB, Yang NS: In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci U S A 1995, 92:2689-2893.
84. Tahara H, Lotze MT: Antitumor affects of Interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995, 2:96-106.
85. Yang G, Hellstrom KE, Mizuno MT, Chen L: In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol 1995, 155:3897-3903.
86. Zhao XM, Byrd VM, McKeehan WL, Reich MB, Miller GG, Thomas JW: Costimulation of human CD4+ T cells by fibroblast growth factor-1 (acidic fibroblast growth factor). J Immunol 1995, 155:3904-3911.
87. Coughlin CM, Wysocka M, Kurzawa HL, Lee WMF, Trinchieri G, Eck SL: B7-1 and Interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995, 55:4980-4987.
88. L was also shown to be adequate for the prevention of programmed cell death induced by T-cell receptor crosslinking, Fas receptor crosslinking or interleukin-2 withdrawal. These results demonstrate that the bcl-2 systems of regulating apoptosis is critical in normal T-cell responses to antigen as well as in the inhibition of programmed cell death induced in tumor cells by genotoxic agents.
89. Guinan EC, Gribben JG, Beussiotis WA, Freeman GJ, Nadler LM: Pivotal role of the B7:CDZ8 pathway in transplantation tolerance and tumor immunity. Blood 1994, 84:3261-3282.